Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Gene expression profile of slowly responding subclones might represent different profiles already at diagnosis and might be used for prediction of outcome

Leukemia volume 23, pages 816–819 (2009)Cite this article

Microarrays for gene expression profiling offers important research tools for novel classification of leukemia's and lymphomas, which may have implications for prognosis and treatment.1, 2 In the field of hematologic malignancies, several papers have demonstrated that the use of microarrays indeed may provide novel information at diagnosis. Using Affymetrix oligonucleotide microarrays, distinct expression profiles have been described for the different cytogenetically defined subgroups of acute lymphoblastic leukemia (ALL).2 Subsequently, also prognostic and disease progression markers have been proposed, ultimately leading to the prospect of patient-tailored therapy.2 However, so far no clear prognostic profiles have been defined. In addition, microarray-based comparisons of paired diagnosis-relapse samples3, 4, 5 from patients with B-precursor ALL have been performed, but so far, not many studies have used this approach. Also, some studies focussed on the identification of glucocorticoid-response genes in children with ALL, comparing diagnosis—day 8 gene expression profiles.6, 7

Treatment of pediatric ALL is increasingly based on the concept of tailoring the intensity of treatment to the risk of treatment failure or success.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams GK et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003; 8: 2951–2959.

    Article  Google Scholar 

  2. Flotho C, Coustan-Smith E, Pei D, Cheng C, Song G, Pui CH et al. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukaemia. Blood 2007; 4: 1271–1277.

    Article  Google Scholar 

  3. Staal FJT, van der Burg M, Wessels LFA, Barendrecht BH, Baert MR, van den Burg CM et al. DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor B-acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers. Leukemia 2003; 17: 1324–1332.

    Article  CAS  PubMed  Google Scholar 

  4. Beesley AH, Cummings AJ, Freitas JR, Hoffmann K, Firth MJ, Ford J et al. The gene expression signature of relapse in pediatric ALL: implications for mechanisms of therapy failure. Br J Hematol 2005; 131: 447–456.

    Article  CAS  Google Scholar 

  5. Bhojwani D, Kang H, Moskowitz NP, Min DJ, Lee H, Potter JW et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a children's Oncology Group Study. Blood 2006; 108: 711–717.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Schmidt S, Rainer J, Riml S, Plomer C, Jesacher S, Achmüller C et al. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukaemia. Blood 2006; 5: 2061–2069.

    Article  Google Scholar 

  7. Tissing WJ, den Boer ML, Meijerink JP, Menezes RX, Swagemakers S, van der Spek PJ et al. Genome-wide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood 2007; 9: 3929–3935.

    Article  Google Scholar 

  8. de Haas V, Verhagen OJ, von dem Borne AEGKr, Kroes W, van den Berg H, van der Schoot CE . Quantification of minimal residual disease in children with oligoclonal B-precursor ALL indicates that the clones that grow out during relapse have the slowest rate of reduction already during induction therapy. Leukemia 2001; 15: 134–140.

    Article  CAS  Google Scholar 

  9. de Haas V, Breunis WB, Verhagen OJ, van den Berg H, van der Schoot CE . Accurate quantification of MRD at day-15, by real-time quantitative PCR identifies also patients with B-precursor ALL at high risk for relapse. Blood 2000; 96: 1619–1620.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was funded by a grant from the Dutch Cancer Society (Grant nr UVA2005-3230).

Author information

Authors and Affiliations

  1. Department of Pediatric Oncology-Hematology, VU Medical Centre, Amsterdam, The Netherlands

    V de Haas

  2. Department of Experimental Immunohematology, Sanquin, Amsterdam

    V de Haas, R Dee, G Cheroutre & C E van der Schoot

  3. The Netherlands,

    V de Haas, R Dee, G Cheroutre & C E van der Schoot

  4. Department of Pediatric Oncology, Emma Children's Hospital/Academic Medical Centre, Amsterdam, The Netherlands

    H van den Berg

Authors
  1. V de Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Dee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Cheroutre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H van den Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C E van der Schoot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V de Haas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Haas, V., Dee, R., Cheroutre, G. et al. Gene expression profile of slowly responding subclones might represent different profiles already at diagnosis and might be used for prediction of outcome. Leukemia 23, 816–819 (2009). https://doi.org/10.1038/leu.2008.315

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.315

This article is cited by

Search

Advanced search

Quick links